A new class of pyridopyrimidinone compounds containing different nitrogenous heterocycles were synthesized starting from the key precursor 2-hydrazinyl-5-phenyl-7-(pyridin-3-yl)pyrido [2,3-d]pyrimidin-4(3H)-one via condensation with series of aromatic aldehydes and cyclization using different reagents as ethyl acetoacetate, ethyl cyanoacetate, diethyl malonate, and ammonium isothiocyanate. e bioassay results showed compound 6 to be highly effective towards three human cancer cell lines (HepG2, PC-3, and HCT-116) in vitro with promising activity values (IC 50 : 0.5 μM) relative to the standard doxorubicin (IC 50 : 0.6 μM). Kinase inhibitory evaluation of compound 6 displays hopeful inhibitory action against BRAF V600E, EGFR, and PDGFRβ at100 μM. e molecular docking studies supported the initial kinase assay.
Introduction
Cancer is a great public health issue characterized by an uncontrolled increase of cancer cells through cell division and the cells undergo modification by their DNA, leading to death [1] [2] [3] . Due to drug resistance and the serious effects of treatment by chemotherapy, the use of available chemotherapeutics is often limited [4] . e combination of chemotherapies with several targets increases selectivity, reduces the resistance, and lowers toxicity towards infected and noninfected cells. Heterocycles have emerged as strong scaffolds for numerous biological considerations [5] and represent a significant part in the designing and detection of novel pharmacologically active entities [6] . e pyridopyrimidine compounds are a group of fused heterocycles that possess various pharmacological applications as antitumor, topoisomerase I inhibitor, adenosine kinase inhibitor, growth regulator, antihepatitis C virus, antiinflammatory, antileishmanial, antiviral, antimicrobial, anticonvulsant, antimycobacterial, CNS depressant, antihypertensive, antiallergic, diuretic, tyrosine kinase inhibitor, and calcium channel antagonist [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Among them, pyrido [2,3-d] pyrimidin-4-ones (A-C) were found to lower cell proliferation in various cancer cell lines through inhibition of various kinases, e.g., TKs, PI3K, and CDK4/6 ( Figure 1 ) [17] [18] [19] . In continuation of our earlier studies that involved synthesis of different other substituted pyridopyrimidine compounds [20] [21] [22] and based on the structural features of pyrido [2,3-d] pyrimidine, this study is designed to synthesize various groups containing different substituents in the phenyl ring at position 5 of the parent compound pyrido [2,3-d] pyrimidinone to further improve the SAR-relationship for their cytotoxicity and also for their inhibitory activity against TKs, CDK4/6, and PI3K enzymes.
Materials and Methods

General Information.
Electrothermal apparatus with open capillary tubes was used in measuring melting points. Shimadzu 435 IR spectrophotometer was used in measuring IR spectra (KBr). Varian Mercury VX-300 NMR spectrophotometer was used in determining NMR spectra using DMSO-d 6 as a solvent and TMS as internal standard. e proposed structures were within ±0.4% of the theoretical values in microanalyses data. Shimadzu GC/MS-QP 2010 plus spectrometer was used in recording mass spectra.
Chemistry
5-Phenyl-7-(pyridin-3-yl)-2-thioxo-2,3-dihydropyrido [2,3-d]pyrimidin-4(1H)-one (3).
In dry DMF (20 mL), equimolar quantities (0.01 mol) of 6-amino-2,3-dihydro-2-thioxopyrimidin-4(1H)-one 1 and α, β-unsaturated ketone 2 were refluxed for 10 h (monitored with TLC). e residue created was gathered and purified from DMF. 
Synthetic Method for Derivatives (5a-g).
In glacial acetic acid (10 mL), equimolar amounts of (0.001 mol) of hydrazinyl derivative 4 and several aromatic aldehydes, benzaldehyde, 4-fluorobenzaldehyde, 4-chlorobenzaldehyde, 4-tolylaldehyde, 4-nitrobenzaldehyde, 4-methoxy benzaldehyde, or 4-N,N-dimethylamino benzaldehyde were refluxed for 5-8 h. After cooling and pouring into crushed ice, the precipitate obtained was purified in DMF/H 2 O. (6) (7) (8) (9) . In glacial acetic acid (15 mL), equimolar amounts (0.001 mol) of hydrazinyl derivative 4 and different reagents, namely, ethyl acetoacetate, ethyl cyanoacetate, diethyl malonate, or ammonium isothiocanate were heated for 3-6 h. e mixture was allowed to cool, poured into ice, and the residue obtained was purified in AcOH. was allowed to react with different aromatic aldehydes to afford 2-arylidene derivatives 5a-g. Compounds 5a-g were confirmed on the basis of their IR spectra and showed strong peaks around the regions 3401-3348, 3234-3195, and 1668-1660 cm −1 corresponding to two amide and carbonyl functions. Furthermore, the methine functions were proved by presence of singlet peaks in the aromatic region in 1 H NMR spectrum and signals around 143 ppm in 13 H NMR spectrum. Treatment of the 2-hydrazinyl intermediate 4 with active methylene, namely, ethyl acetoacetate, ethyl cyanoacetate, diethyl malonate, or ammonium isothiocyanate afforded the corresponding 5-substituted pyrazolones and triazolopyrimidines 6-9 (Scheme 1). e new pyrazolone ring linked to the pyridopyrimidine backbone in compound 6 was proved with the appearance of strong bands at 3214 and 1725 cm 
2-[2-(4-Methylbenzylidene)hydrazinyl]-5-phenyl-7-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (5d
2-[2-(4-Nitrobenzylidene)hydrazinyl]-5-phenyl-7-(pyridin-3-yl)pyrido[2,3-d]-pyrimidin-4(3H)-one (5e
2-[2-(4-Methoxybenzylidene)hydrazinyl]-5-phenyl-7-(pyridin-3-yl)pyrido[2,3-d]pyrimidin-4(3H)-one (5f
2-[2-(4-Dimethylaminobenzylidene)hydrazinyl]-5-phenyl-7-(pyridin-3-yl)pyrido[2,3-d]-pyrimidin-4(3H)-one (5g
Synthetic Method for Derivatives
2-(3-Methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)-5-phenyl-7-(pyridin-3-yl)pyrido-[2,3-d]-pyrimidin-4(3H)-one (6)
.
2-(3-Amino-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)-5-phenyl-7-(pyridin-3-yl)pyrido-[2,3-d]-pyrimidin-4(3H)-one (7)
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Finally, the new 3-aminotriazole ring fused with pyridopyrimidine moiety in 9 was proved in the IR spectra by the existence of bands at 3460 and 3317 cm −1 referred to NH 2 and NH functions besides other band at 1669 cm −1 due to carbonyl of pyridopyrimidine moiety. 1 H NMR spectrum displayed two singlets at 5.60 and 12.55 attributed to NH 2 and NH protons of the new fused ring. 13 C NMR spectrum displayed the carbons at their expected regions, and MS gave a [M + ]-ion peak at m/z 355 equivalents to the molecular formula of 9.
Biology
In Vitro Cytotoxic Screening against HepG2, PC-3, and
HCT-116 Cell Lines. Anticancer evaluation of the newly obtained products represented in Figure 2 was screened against three human cancer cell lines (HepG2, PC3, or HCT-116) [23] .
e tested compounds that displayed inhibitory effect more than 90% referring doxorubicin as a standard drug (IC 50 0.6 μM) were chosen for IC 50 examination (concentrations required for 50% inhibition of cell viability). e in vitro screening of compounds 3-9 at 100 μM ( Figure 3 ) exhibited remarkable anticancer activities, and compound 6 showed promising potency against hepatic cancer cell line (anti-HepG2) with (IC 50 � 0.5 μM).
Structure-Activity Relationships.
e cytotoxic screening results revealed that thioxo precursor 3 displayed poor anticancer activity against all cancer cell lines. Upon converting the thioxo group in 3 to hydrazide in 4, antihepatic cancer (HepG2) effect was greatly increased as a result of the presence of the hydrophilic electron-rich nature in compound 4 which causes the electron factor to give a positive impact on the antiproliferative properties. Attachment of the pyrazole ring as a substituent at position 2 of the backbone moiety as in compounds 6, 7, and 8 afforded the highest potency of anticancer activity. Compound 6 that carried 5-methyl-3-oxopyrazole exhibited the highest activity against all the tested cell lines. e activity was reduced and shifted toward the PC-3 cell line after replacement of the 5-methyl-3-oxopyrazole nucleus at 6 by 3-amino-5-oxopyrazol in 7. Upon replacing the mentioned pyrazole moiety in 6 by 3,5-dioxopyrazole in 8, or by fused triazolo [4,3-a] pyrimidine in 9, the activity profile was changed.
Kinase Inhibition Screening.
According to the data of cytotoxic assay, the highly potent derivative 6 was chosen for in vitro inhibition assessment against a list of different protein, AKT1, AKT2, BRAF (V600E), CDK2/cyclin A1, CHK1, EGFR, PDGFRβ, and c-RAF kinases at 100 μM utilized the radiometric or ADP-Glo assay procedure. ree of the tested kinases (BRAF V600E, EGFR, and PDGFRβ) were highly inhibited by more than 90% with the highest inhibition recorded with EGFR at 97%. On the contrary, compound 6 appeared to partially activate the c-RAF kinase with a rise in counts of 37% over the control substrate rates (Table 1 , Figure 4 ).
Molecular Docking Study.
Molecular docking was used to analyze the supposed binding mode of the designed compound with CDK6 and EGFR to better understand the mechanism of inhibition. For the docking studies, the crystal structure of the complex CDK6 and EGFR has been chosen (PDB code 5L2I [24] and PDB code 4HJO [25] ). e most active compound 6 in the current study was docked into the CDK6 and EGFR kinase's putative active site. For the receptor preparation, the Molecular Operating Environment software package MOE ® 2015 [26] has been used by means of the removal of water molecules and the addition of hydrogen atoms. MOE has also been used for the graphic structure of ligands 3D and then saved on data lists after minimizing structure and geometries energy. For each receptor, the pockets were then used to dock ligands after setting London dG to scoring function and GBVI/WSA dG to re scoring function. erefore, the scoring and RMSD (root-mean-square deviation) values for the best conformation of each ligand with different receptors are shown in Table 2 , as well as 2D and 3D figures of each selected conformation are shown in Figures 3 and 4 . Docking simulation of compound 6 into kinase domain of CDK6 and EGFR postulated the pivotal function of both the backbone moiety and the side chain substituent (Figures 5  and 6 ). 
Conclusions
A library of substituted pyridopyrimidines 3-9 were designed and screened for their cytotoxicity. ere are potent growth inhibitory effects against hepatic, prostate, and colon cancer cells lines, in comparison with doxorubicin as positive control. Regarding HepG2 cell line, compound 6 showed the greatest inhibitory activities against hepatic cancer (HepG2) with inhibition percent (IC 50 � 0.5 μM) more potent than doxorubicin (IC 50 � 0.6 μM). A molecular docking study of compound 6 into the ATP binding site of EGFR exhibited identical binding as erlotinib.
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